Skip to main content
. 2022 Aug 26;12:941496. doi: 10.3389/fonc.2022.941496

Table 3.

Sarcopenia prevalence during neoadjuvant chemotherapy.

Group After chemotherapy
No sarcopenia Sarcopenia Total
Before chemotherapy No sarcopenia 208 (92.86%) 29 (31.18%) 237 (74.76%)
Sarcopenia 16 (7.14%) 64 (68.62%) 80 (25.24%)
Total 224 (100%) 93 (100%) 317 (100%)

Pearson χ2(1) = 132.48, p = 0.000.